# Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer

> **NCT05010954** · PHASE3 · COMPLETED · sponsor: **Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.** · enrollment: 400 (actual)

## Conditions studied

- Duodenal Ulcer

## Interventions

- **DRUG:** LXI-15028 50mg group
- **DRUG:** Lansoprazole 30mg group

## Key facts

- **NCT ID:** NCT05010954
- **Lead sponsor:** Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-18
- **Primary completion:** 2022-09-28
- **Final completion:** 2022-09-28
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2023-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010954, "Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05010954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*